These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 21330939)

  • 1. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies.
    McCannel CA
    Retina; 2011 Apr; 31(4):654-61. PubMed ID: 21330939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Fileta JB; Scott IU; Flynn HW
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):143-9. PubMed ID: 24635156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
    Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
    Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
    Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD; Anderson NG
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab.
    Fintak DR; Shah GK; Blinder KJ; Regillo CD; Pollack J; Heier JS; Hollands H; Sharma S
    Retina; 2008; 28(10):1395-9. PubMed ID: 18827737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
    Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
    Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.
    Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C;
    Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics.
    Park Y; Kim KS; Park YH
    J Ocul Pharmacol Ther; 2013 Dec; 29(10):900-5. PubMed ID: 24067061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection.
    Storey P; Dollin M; Rayess N; Pitcher J; Reddy S; Vander J; Hsu J; Garg S;
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):235-42. PubMed ID: 25940556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics.
    Li AL; Wykoff CC; Wang R; Chen E; Benz MS; Fish RH; Wong TP; Major JC; Brown DM; Schefler AC; Kim RY; OʼMalley RE
    Retina; 2016 Jul; 36(7):1349-56. PubMed ID: 26655622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.
    Garg SJ; Dollin M; Hsu J; Storey P; Vander JF
    Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1028-34. PubMed ID: 26599245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.